source
- FDA places Bright Minds seizure drug BMB-101 on partial hold over mouse toxicity, shares plungeThe U.S. Food and Drug Administration issued a partial clinical hold on BMB-101, an experimental seizure treatment from Bright Minds Biosciences, after regulators identified toxicity concerns in pr…
- AbbVie signs up to $757M deal with Beijing's Brise Pharma for two preclinical migraine candidatesAbbVie announced a discovery and commercialization agreement with Brise Pharma, a Beijing-based biotech company. The partnership covers two preclinical migraine programs and is valued at up to $75…